Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Allorion Therapeutics
AddedFeb 17, 2024
UpdatedJul 2, 2026
Allorion Therapeutics

Allorion Therapeutics

Allorion Therapeutics: Developing small molecule drugs for cancer and autoimmune diseases globally.

HQ
Natick, MA, US
Founded
2020
Overview
Analysis
Compare
Fundraising
Employees
News
Website

Founded with a mission to develop next-generation targeted drugs, Allorion Therapeutics focuses on creating small molecule therapeutics for cancer and autoimmune diseases. With operations in Natick, Massachusetts, and Guangzhou, China, the company leverages innovative discovery platforms and a robust R&D team to address unmet patient needs. Allorion's science- and data-driven approach aims to produce globally competitive drugs, and it seeks to enhance commercialization through partnerships with leading pharmaceutical companies.

Notable figures affiliated with Allorion Therapeutics include esteemed scientists and industry experts who drive its innovative research and development efforts. The company has garnered attention for its promising drug pipeline and strategic collaborations. By advancing precision medicine, Allorion has made significant strides in improving treatment options for complex diseases, thereby impacting global healthcare positively.

Allorion Therapeutics - Products & Services

  • Allosteric Inhibitor Screening + Synthetic Lethality Discovery Platform logo

    Allosteric Inhibitor Screening + Synthetic Lethality Discovery Platform

    Allosteric screening and synthetic lethality platforms with 200k library.

  • ARTS-023 / AVZO-023 (CDK4 selective inhibitor) logo

    ARTS-023 / AVZO-023 (CDK4 selective inhibitor)

    Selective CDK4 inhibitor for HR+ breast cancer partnered with Avenzo.

  • EGFR L858R allosteric inhibitor program logo

    EGFR L858R allosteric inhibitor program

    Preclinical allosteric EGFR L858R inhibitor program for oncology.

  • ARTS-021 / AVZO-021 (CDK2 selective inhibitor) logo

    ARTS-021 / AVZO-021 (CDK2 selective inhibitor)

    Potent selective CDK2 inhibitor for CCNE1-amplified and breast cancers.

  • ARTS-011 (TYK2 allosteric inhibitor) logo

    ARTS-011 (TYK2 allosteric inhibitor)

    Highly selective TYK2 allosteric inhibitor for autoimmune disorders.

Allorion Therapeutics - Similar Companies

Orionis Biosciences logo

Orionis Biosciences

orionisbio.com

Azora Therapeutics logo

Azora Therapeutics

Allyx Therapeutics logo

Allyx Therapeutics

allyxthera.com

Allterum Therapeutics logo

Allterum Therapeutics

allterum.com

Allinaire Therapeutics logo

Allinaire Therapeutics

allinaire.com

Allogene Therapeutics logo

Allogene Therapeutics

allogene.com

Orion BioScience logo

Orion BioScience

Alloplex Biotherapeutics logo

Alloplex Biotherapeutics

Orna Therapeutics logo

Orna Therapeutics

Orphion Therapeutics logo

Orphion Therapeutics

Alterome Therapeutics logo

Alterome Therapeutics

alterome.com

Athos Therapeutics logo

Athos Therapeutics

athostx.com

Alloy Therapeutics logo

Alloy Therapeutics

alloytx.com

Aristea Therapeutics logo

Aristea Therapeutics

Orphan Star Therapeutics logo

Orphan Star Therapeutics

Allorion Therapeutics - Quick Facts

Who are Allorion Therapeutics' competitors?

Companies similar to Allorion Therapeutics include Orionis Biosciences, Azora Therapeutics, Allyx Therapeutics and Allterum Therapeutics.

When was Allorion Therapeutics founded?

Allorion Therapeutics was founded in 2020.

Where is Allorion Therapeutics' headquarters located?

Allorion Therapeutics' headquarters is located in Natick, MA, US.

When was Allorion Therapeutics' last funding round?

Allorion Therapeutics' most recent funding round was for $50M (USD) in March 2023.

How much has Allorion Therapeutics raised to-date?

As of Mar 9, 2023, Allorion Therapeutics has raised a total of $90M (USD).

How many employees does Allorion Therapeutics have?

Allorion Therapeutics has 27 employees as of Feb 4, 2024.

Allorion Therapeutics - Classification

Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Tags
  • Biotech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 13 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified